JDCAI
MRNA icon

Johnson Dunn Capital Advisors Inc’s Moderna MRNA Stock Holding History

Johnson Dunn Capital Advisors Inc’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$506K Buy
+2,628
New +$283K 0.36% 73

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Johnson Dunn Capital Advisors Inc's MRNA Position: Q3 2026 in Review

Johnson Dunn Capital Advisors Inc opened a new position in Moderna (MRNA) in Q3 2026: 2,628 shares worth $506K. The stake represents 0.36% of the portfolio and ranks #73 among its holdings.

737 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Johnson Dunn Capital Advisors Inc held 2,628 shares of Moderna worth $506K as of Q3 2026.
  • Moderna was a new Johnson Dunn Capital Advisors Inc position in Q3 2026.
  • Moderna made up 0.36% of Johnson Dunn Capital Advisors Inc's portfolio in Q3 2026, its #73 holding.
  • 737 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Johnson Dunn Capital Advisors Inc's 13F filing for Q3 2026, filed 12 Nov 2026.